|Bid||16.70 x 800|
|Ask||16.83 x 1200|
|Day's Range||16.09 - 17.99|
|52 Week Range||11.00 - 26.74|
|Beta (3Y Monthly)||-0.03|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.
Fibrocell (FCSC) collaborates with Castle Creek to develop/commercialize its gene therapy candidate, FCX-007, for the rare skin disease of recessive dystrophic epidermolysis bullosa. Stock jumps.
Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.
Vertex (VRTX) gains a nod from Health Canada for Kalydeco to treat cystic fibrosis (CF) in children aged 12 to less than 24 months.
Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit a 52-week peak Thursday. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 27) • Aevi ...
Does Merus N.V. (NASDAQ:MRUS) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on research activities, so it is no wonder why they tend to generate millions in profits […]
Merus NV (NASDAQ:MRUS), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is MRUS will Read More...
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.